IMFINZI® (Durvalumab) + IMJUDO® (Tremelimumab-Actl) Improves PFS in Early Liver Cancer

AZ claims another win for Imfinzi in frontline liver cancer

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically

AstraZeneca's Emerald-3 Trial Shows Promise in Early-Stage Liver Cancer

AstraZeneca has announced positive interim results from its Phase 3 Emerald-3 trial, demonstrating that a combination of Imfinzi, Imjudo, and Lenvima, paired with transarterial chemoembolization (TACE), significantly improved progression-free survival (PFS) in patients with unresectable locoregional hepatocellular carcinoma. This achievement marks a potential breakthrough for patients who typically face high rates of disease recurrence following…

AstraZeneca Reports Positive Phase III EMERALD-3 Results In Unresectable Liver Cancer

Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca plc (LON:AZN)  Imfinzi (durvalumab) in combination with Imjudo (tremelimumab), lenvatinib and transarterial chemoembolisation (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for emb…